Immunovaccine Announces Webcast of R&D Update and Investor Event
March 27 2018 - 7:05AM
Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage
immuno-oncology company, announced today that it will webcast its
‘R&D Update and Investor Event,’ which is being held on
Tuesday, April 10, 2018 in New York.
The program will begin at 12:00 p.m. ET and will feature an
overview of the Company’s novel approach to targeted T cell
therapy. External key opinion leaders (KOLs) and Immunovaccine
management will present perspectives on the Company’s proprietary
immune-stimulating technology, its novel mechanism of action, and
its clinical applications and potential benefits.
A live broadcast of the event will be available on the Investors
section of the Immunovaccine website at http://ir.imvaccine.com.
Please log on through Immunovaccine’s website approximately 10
minutes before the scheduled start time. A replay of the webcast
will be archived on the Company’s website following the event.
If you are a member of the investment community and would like
to attend the event, please send an email to
tracy.sebastian@westwicke.com to receive additional
information.
About Immunovaccine Immunovaccine
Inc. is a clinical stage biopharmaceutical company dedicated
to making immunotherapy more effective, more broadly applicable,
and more widely available to people facing cancer and other serious
diseases. Immunovaccine develops T cell-activating cancer
immunotherapies based on the Company’s proprietary drug delivery
platform. This patented technology provides controlled and
prolonged exposure to a broad range of immunogenic stimuli.
Immunovaccine has advanced two T cell-activating therapies for
cancer through Phase 1 human clinical trials and is currently
conducting a Phase 1b study with Incyte Corporation assessing its
lead cancer therapy, DPX-Survivac, as a combination therapy in
ovarian cancer. The Company is also exploring additional
applications of its platform, including DPX-RSV, an innovative
vaccine candidate for respiratory syncytial virus (RSV), which has
recently completed a Phase 1 clinical
trial. Immunovaccine also has ongoing research projects
in malaria and the Zika virus. Connect
at www.imvaccine.com.
Immunovaccine Forward-Looking Statements This
press release contains forward-looking information under applicable
securities law. All information that addresses activities or
developments that we expect to occur in the future is
forward-looking information. Forward-looking statements are based
on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a
representation that any of them will be achieved. Actual results
may differ materially from those set forth in this press release
due to risks affecting the Company, including access to capital,
the completion of clinical trials and receipt of all regulatory
approvals. Immunovaccine Inc. assumes no responsibility
to update forward-looking statements in this press release except
as required by law.
Contacts for Immunovaccine:
MEDIA Mike Beyer, Sam Brown Inc. T:
(312) 961-2502 E: mikebeyer@sambrown.com
INVESTOR RELATIONS Pierre Labbé, Chief
Financial Officer T: (902) 492-1819 E: info@imvaccine.com
Patti Bank, Managing Director, Westwicke
Partners O: (415) 513-1284 T: (415) 515-4572
E: patti.bank@westwicke.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024